Cargando…
Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product
BACKGROUND: Botulism is a rare, serious, and sometimes fatal paralytic illness caused by exposure to neurotoxins produced by Clostridium botulinum bacteria. Patients with documented or suspected exposure to botulinum toxin serotypes A-G can be treated with BAT(®) [Botulism Antitoxin Heptavalent (A,...
Autores principales: | Anderson, Deborah M., Kumar, Veena R., Arper, Diana L., Kruger, Eliza, Bilir, S. Pinar, Richardson, Jason S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837762/ https://www.ncbi.nlm.nih.gov/pubmed/31697731 http://dx.doi.org/10.1371/journal.pone.0224700 |
Ejemplares similares
-
Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product
por: Beliveau, Martin, et al.
Publicado: (2022) -
Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs
por: Barker, Douglas, et al.
Publicado: (2019) -
Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model
por: Emanuel, Andrew, et al.
Publicado: (2019) -
Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)—(Equine) (BAT(®)) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review
por: Parrera, Geraldine S., et al.
Publicado: (2021) -
Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques
por: Kodihalli, Shantha, et al.
Publicado: (2017)